Composition of oral solid medicine having good vivo behaviors
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A kind of technology of composition and medicine, applied in the field of oral solid pharmaceutical composition
Active Publication Date: 2013-05-01
北京睿琪生物医药科技有限公司
View PDF4 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Although this method is believed to reduce the first-pass effect of the drug, the rapid rise and fall of the drug concentration in the blood may require frequent dosing to keep the drug at the level of the therapeutic window for an extended period of time.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0059] Embodiment 1: prepare pharmaceutical composition (tablet) of the present invention
[0060] prescription:
[0061]
[0062] Preparation method: pass the prescription amount of active ingredients, methylcellulose K100, microcrystalline cellulose 60mg, and glyceryl behenate 888ATO through a 60-mesh sieve, and mix them evenly in a mixer; then mix xanthan gum with an appropriate amount of water Dissolve as a binder, granulate with the above materials, dry, pass the dry granules through a 20-mesh sieve; then pass another part of microcrystalline cellulose, silicon dioxide 244FP, and talcum powder through a 60-mesh sieve, mix with the above-mentioned dry granules, and press into tablets .
Embodiment 2
[0063] Embodiment 2: prepare pharmaceutical composition (tablet) of the present invention
[0064] prescription:
[0065]
[0066] Preparation method: mix the active ingredient, lactose, microcrystalline cellulose, hydrogenated vegetable oil, hydroxypropyl methylcellulose 2208 and fatty acid glycerides in the prescribed amount, and then add ethyl cellulose aqueous suspension (solid content 6 %), mix evenly, granulate, dry, pass the dry granules through a 20-mesh sieve, add talcum powder, mix evenly, press into tablets, and you get it.
Embodiment 3
[0067] Embodiment 3: prepare pharmaceutical composition (tablet) of the present invention
[0068] prescription:
[0069]
[0070] Preparation method: mix the active ingredient, starch, microcrystalline cellulose and hydroxypropyl methylcellulose in the prescribed amount evenly, granulate with a binder, dry, pass the dry granules through a 20-mesh sieve, add magnesium stearate and mix evenly , pressed into tablets, ready to use.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
particle diameter
aaaaa
aaaaa
particle diameter
aaaaa
aaaaa
particle diameter
aaaaa
aaaaa
Login to view more
Abstract
The invention relates to a composition of an oral solid medicine having good vivo behaviors. The composition of the solid medicine has unit dosage forms and is measured with a releasing rate measuring method, and the release amounts of each unit dosage form are 15%-45%, 40%-80% and more than 80% of the labelled amount when the time period reaches one hour, four hours or eight hours respectively. The composition of the oral solid medicine can be applied to cerebrovascular diseases, improves brain metabolism and psychiatric symptoms, activates the respiratory activity of brain mitochondria, and improves brain energy metabolism of cerebral ischemia and the utilization rate of glucose inside the brain, so that the production of triphosadenine inside the brain is increased, the brain mitochondria are prevented from producing lipid peroxidase, and the membrane barrier caused by lipid peroxidation of a brain mitochondrial membrane and brain function damages caused by chronic cerebrovascular diseases, cerebral traumas and the like are prevented; and mental and behavioral disorders such as subjective symptoms, language barriers, dysphoria, depression, hypomnesia, mental decline and the like are improved.
Description
technical field [0001] The invention relates to an oral solid pharmaceutical composition with good behavior in vivo, which can be used for the treatment or prevention of nervous system diseases. Background technique [0002] Neuronal damage, neurodegenerative diseases and syndromes (Alzheimer's disease, multiple sclerosis, Friedrich's ataxia, brain and spinal cord injuries and neurotrauma, stroke, Parkinson's disease, alcoholism and narcolepsy, postoperative recovery syndrome and postanesthesia recovery syndrome) and many other conditions require effective treatment and prevention. [0003] Postoperative stroke and cognitive deficit (POSCD) syndrome is common, especially in older adults undergoing major surgical procedures such as heart surgery or hip replacement. In North America, more than 2.5 million such surgical procedures are performed each year, and the incidence of POSCD exceeds 30%. There is an urgent need for interventional therapy, and there are not enough treat...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more